Robert hugin net worth3/20/2023 ![]() ![]() ![]() We look forward to launching the psoriasis indication later this quarter following FDA action. Scott will detail many of the metrics that give us the confidence that our team is fully capitalizing on the opportunity of building a new market for this innovative oral compound. team launched Otezla for psoriatic arthritis in April and are making outstanding progress in building the foundation of a first-class launch. Over the next few quarters, we expect significant increased visibility on our next generation of registration track studies.īuilding a market-leading inflammation and immunology franchise is also a key corporate initiative. Mark will outline some of the key studies that are accelerating our impact in the hematology oncology field. In the second half of the year, collaborations are positioned to evaluate Abraxane, Revlimid, CC-486 and other pipeline assets in combination regimens with emerging immuno-oncology therapies. We’re aggressively moving these programs forward with our partners, Acceleron and Agios.ĭuring the first half of the year, our oncology programs were advanced by the initiation of Phase III studies testing Abraxane as an adjutant treatment in patients with surgically resected pancreatic cancer and as maintenance therapy in patients with squamous non-small cell lung cancer. The future of our hematology franchise was further enhanced through meaningful progress on strategic collaborations, including ACE-011 and ACE-536 in beta thalassemia, and exciting data in targeted relapse refractory AML with AG-221. During the quarter, we strengthened our hematology product portfolio with important new clinical data in MDS, AML, and mantle cell lymphoma. We’re making exceptional progress in building for the future. ![]() Jacquie and Mark will discuss the results and our outlook in greater depth in a few minutes.Ĭapturing the full value of our franchises is the highest order of corporate priority. This strong performance supports raising our full-year financial guidance. Increased Revlimid duration of therapy and accelerating global launches of pomalidomide and Abraxane in pancreatic cancer fueled substantial volume and revenue growth. The strong revenue and earnings growth reported this morning reflect the excellent operating performance of our teams. ![]() Our businesses across functions and geographies have outstanding momentum. Outstanding results produce the resources that allow us to invest in the discovery and development of tomorrow’s transformational therapies, and our teams across the globe are delivering. Operational excellence is the foundation of our business model. I appreciate the opportunity to update you on the excellent results of the quarter and the significant progress achieved advancing strategic corporate initiatives. Thanks Patrick, and thank you everyone for joining us this morning. I would now like to turn the call over to Bob. Finally, a reconciliation of the adjusted financial measures to the most comparable GAAP measures are available as part of the earnings release. These statements speak only as of today’s date and we undertake no duty to update or revise them. A description of these risks can be found in our most recent 10-Q on file with the SEC. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Joining me in the room today with prepared remarks are Bob Hugin, our Chairman and Chief Executive Officer Jacquie Fouse, our Chief Financial Officer Mark Alles, who is Global Head of our Hematology and Oncology franchise and the Global Head of our Inflammation and Immunology franchise, Scott Smith.Īs a reminder, during today’s call we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. The press release reporting our financial results in addition to the presentation for today’s webcast can be accessed by going to the Investor Relations section of the corporate website at. Thanks, Nicole, and welcome everyone to our second quarter earnings conference call. I would now like to turn the conference over to Patrick Flanigan, Vice President, Investor Relations at Celgene. I would like to remind you that this call is being recorded. All participants will be in a listen-only mode until the question and answer session at the end of the conference. Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |